Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Chief Commercial Officer | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02 | Direct | 1,000,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). F2: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).
F2: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:33 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 1,000,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001171843-26-000059 · ownership.xml · derivative · entry 1 Prasad Arjun · CIK 0002102138 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: COMMON STOCK · 1,000,000 shares Expires 2036-01-02 F1 · shares: The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). F2 · derivative.exercise_date: The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.